Role of Rajaswalacharya On different patterns of menstrual cycle

Role of Rajaswalacharya on different patterns of menstrual cycle

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/033932

Enrollment

120

Registered

2021-06-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N00-N99- Diseases of the genitourinary system Health Condition 2: N921- Excessive and frequent menstruation with irregular cycle

Interventions

Intervention1: Rajaswalacharya: A diet regime of Shali rice, Yava (Barley), Ghee, Milk Route: Oral Frequency: OD Dose: Three time a day Control Intervention1: Placebo: Placebo Dose: 1 capsule of Mishr

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of age group 18 to 45 years complaining of chief complaint of dysmenorhoea/ abnormal uterine bleeding (AUB)/ oligomenorrhoea. 2. Subjects suffering with dysmenorhoea/ abnormal uterine bleeding (AUB)/ oligomenorrhoea for 2 consecutive cycles. For Group - A: dysmenorhoea with scanty or average amount of menses For Group - B: Heavy menstrual bleeding (amount >80ml) or Prolonged menstrual bleeding (duration >7 days) or Frequent menstrual cycle (interval For Group C - Oligomenorrhoea: Interval between 2 cycle exceeding more than 35 days but not more than 50 days

Exclusion criteria

Exclusion criteria: 1. Subjects suffering from venereal diseases. 2. Subjects suffering from systemic diseases. 3. Subjects having organic pathology of uterus and adnexae eg. Fibroid uterus - size of fibroid less than 2 cm. 4. Subjects using intra uterine contraceptive devices. 5. Subjects with H/O hypothyroidism and hyperthyroidism with DUB. 6. Pregnant women. 7. Patients having bleeding due to abortion. 8. Patients having bleeding after menopause. 9. Patients having coagulation disorders. 10. Any type of malignancy. 11. Drug induced amenorrhoea/oligomenorrhoea/ abnormal uterine bleeding (AUB) 12. Patients taking OCPs 13. Patient having congenital and structural abnormality of uterus. 14. Haemoglobin less than 9 gm%.

Design outcomes

Primary

Measure	Time frame
To check the effectiveness of Rajaswala charya in the management of different patterns of menstrual cycleTimepoint: 20 weeks	—

Secondary

Measure	Time frame
To develop standard protocol of Rajaswala charya. 2 To conduct a survey of the prevalence and incidence of different patterns of menstrual cycle. Timepoint: 20 weeks	—

Countries

India

Contacts

Public ContactBharathi Kumaramanglam

hetaldave2406@gmail.com9251758867

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026